These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32856157)

  • 21. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.
    Fujinaga S; Ohtomo Y; Hara S; Umino D; Someya T; Shimizu T; Kaneko K
    Pediatr Nephrol; 2008 Oct; 23(10):1877-82. PubMed ID: 18414900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
    Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
    Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.
    Lu Z; Song J; Mao J; Xia Y; Wang C
    Med Sci Monit; 2017 May; 23():2333-2339. PubMed ID: 28515415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G; Foster J; Berard R; Mai I; Lepage N
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of mycophenolic acid in severe lupus nephritis.
    Lertdumrongluk P; Somparn P; Kittanamongkolchai W; Traitanon O; Vadcharavivad S; Avihingsanon Y
    Kidney Int; 2010 Aug; 78(4):389-95. PubMed ID: 20531457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).
    Sagcal-Gironella ACP; Merritt A; Mizuno T; Dharnidharka VR; McDonald J; DeGuzman M; Wahezi D; Goilav B; Onel K; Kim S; Cody E; Wu EY; Cannon L; Hayward K; Okamura DM; Patel PN; Greenbaum LA; Rouster-Stevens KA; Cooper JC; Ruth NM; Ardoin S; Cook K; Borgia RE; Hersh A; Huang B; Devarajan P; Brunner H
    J Clin Trials; 2024; 14(4):. PubMed ID: 39035447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
    Parant F; Rivet C; Boulieu R; Gagnieu MC; Dumortier J; Boillot O; Lachaux A
    Ther Drug Monit; 2009 Dec; 31(6):727-33. PubMed ID: 19881404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
    Woillard JB; Bader-Meunier B; Salomon R; Ranchin B; Decramer S; Fischbach M; Berard E; Guigonis V; Harambat J; Dunand O; Tenenbaum J; Marquet P; Saint-Marcoux F
    Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation.
    van Hest R; Mathot R; Vulto A; Weimar W; van Gelder T
    Ther Drug Monit; 2005 Apr; 27(2):163-7. PubMed ID: 15795646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.